GETI.B

210.9

+0.72%↑

CAMX

604.5

+1.77%↑

BIOAB

318.8

+4.8%↑

EKTA.B

55.8

0%↓

VITR

138.9

-1%↓

GETI.B

210.9

+0.72%↑

CAMX

604.5

+1.77%↑

BIOAB

318.8

+4.8%↑

EKTA.B

55.8

0%↓

VITR

138.9

-1%↓

GETI.B

210.9

+0.72%↑

CAMX

604.5

+1.77%↑

BIOAB

318.8

+4.8%↑

EKTA.B

55.8

0%↓

VITR

138.9

-1%↓

GETI.B

210.9

+0.72%↑

CAMX

604.5

+1.77%↑

BIOAB

318.8

+4.8%↑

EKTA.B

55.8

0%↓

VITR

138.9

-1%↓

GETI.B

210.9

+0.72%↑

CAMX

604.5

+1.77%↑

BIOAB

318.8

+4.8%↑

EKTA.B

55.8

0%↓

VITR

138.9

-1%↓

Home・Akciju saraksts・Vivesto AB

Vivesto AB

Slēgts

0.22

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.22

Max

0.22

Galvenie mērījumi
By Trading Economics
Ienākumi	2.3M -7.2M
EPS	-0.013
Darbinieki	4

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-4.4M 74M
Iepriekšējā atvēršanas cena	0.22
Iepriekšējā slēgšanas cena	0.22

Vivesto AB Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. dec. 20:41 UTC

Peļņas

Galvenie tirgus virzītāji

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

2025. g. 4. dec. 18:14 UTC

Iegādes, apvienošanās, pārņemšana

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

2025. g. 4. dec. 17:43 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

2025. g. 4. dec. 17:01 UTC

Peļņas

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

2025. g. 4. dec. 23:45 UTC

Tirgus saruna

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

2025. g. 4. dec. 23:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 4. dec. 21:54 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 4. dec. 21:54 UTC

Tirgus saruna

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

2025. g. 4. dec. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 4. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 4. dec. 21:48 UTC

Tirgus saruna

Scales Hits Mark With Earnings Guidance -- Market Talk

2025. g. 4. dec. 21:37 UTC

Peļņas

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

2025. g. 4. dec. 21:36 UTC

Peļņas

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

2025. g. 4. dec. 20:15 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 4. dec. 20:15 UTC

Tirgus saruna

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

2025. g. 4. dec. 20:04 UTC

Tirgus saruna

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

2025. g. 4. dec. 19:54 UTC

Tirgus saruna

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

2025. g. 4. dec. 19:44 UTC

Iegādes, apvienošanās, pārņemšana

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

2025. g. 4. dec. 19:44 UTC

Iegādes, apvienošanās, pārņemšana

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

2025. g. 4. dec. 19:44 UTC

Iegādes, apvienošanās, pārņemšana

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

2025. g. 4. dec. 19:33 UTC

Tirgus saruna

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

2025. g. 4. dec. 19:01 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

2025. g. 4. dec. 19:01 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

2025. g. 4. dec. 19:01 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

2025. g. 4. dec. 19:01 UTC

Iegādes, apvienošanās, pārņemšana

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

2025. g. 4. dec. 18:58 UTC

Tirgus saruna

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

2025. g. 4. dec. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 4. dec. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 4. dec. 16:41 UTC

Tirgus saruna

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

2025. g. 4. dec. 16:33 UTC

Tirgus saruna

Peļņas

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Salīdzinājums

Cenas izmaiņa

Vivesto AB Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.